Organic anion transporting polypeptide (OATP) 1B1 plays an important role in the hepatic uptake of many drugs, and the evaluation of OATP1B1-mediated drug-drug interactions (DDIs) is emphasized in the latest DDI (draft) guidance documents from U.S. and E.U. regulatory agencies. It has been suggested that some OATP1B1 inhibitors show a discrepancy in their inhibitory potential, depending on the substrates used in the cell-based assay. In this study, inhibitory effects of 14 compounds on the OATP1B1-mediated uptake of the prototypical substrates [ values, respectively. Also, the clinically relevant OATP inhibitors rifampin and cyclosporin A exhibited up to 12-and 6-fold variation in their IC 50 values, respectively. Regardless of the inhibitors tested, the most potent OATP1B1 inhibition was observed when [ 3 H]E 2 G was used as a substrate. Mutual inhibition studies of OATP1B1 indicated that E 2 G and E 1 S competitively inhibited each other, whereas BSP noncompetitively inhibited E 2 G uptake. In addition, BSP inhibited E 1 S in a competitive manner, but E 1 S caused an atypical kinetics on BSP uptake. This study showed substratedependent inhibition of OATP1B1 and demonstrated that E 2 G was the most sensitive in vitro OATP1B1 probe substrate among three substrates tested. This will give us an insight into the assessment of clinically relevant OATP1B1-mediated DDI in vitro with minimum potential of false-negative prediction.
Introduction
Pharmacokinetic drug-drug interactions (DDIs) involve altered pharmacokinetics of a drug by a concomitant medication, and consequently affect pharmacologic efficacy and/or adverse effects. As DDIs can cause life-threatening adverse events, particularly when the therapeutic range of a substrate drug is narrow, evaluation of the DDI potential of new chemical entities is an integral part of drug development from the viewpoint of clinical safety.
During this decade, research on membrane transporters has also achieved significant progress and revealed a major, clinically important role of membrane transporters in the pharmacokinetics of a broad range of drugs (Mizuno et al., 2003) . Along with this, inhibition of membrane transporters has been recognized as one of the underlying mechanisms of pharmacokinetic DDIs (Shitara et al., 2005) . In 2010, International Transporter Consortium published a so-called "transporter white paper," in which a systematic approach to transporter-mediated DDIs during drug development was proposed (Giacomini et al., 2010) . Furthermore, the importance of the evaluation of transporter-mediated DDI potential of an investigational drug has been emphasized in the latest DDI draft guidance materials and guidelines released by the U.S. Food and Drug Administration and the European Medicines Agency, respectively (Center for Drug Evaluation and Research, 2012; Committee for Human Medicinal Products, 2012) .
Potential risk evaluation of DDIs involving transporters as well as drug-metabolizing enzymes at nonclinical levels has become a crucial task for scientists in pharmaceutical industries as they seek to prioritize and develop drug candidates. Two models have been proposed for quantitative prediction of transporter-mediated DDIs: a static model and a dynamic (physiologically-based pharmacokinetic) model. The static model assumes a constant concentration of inhibitors (Hirano et al., 2006; Sharma et al., 2012) , whereas the time-course of inhibitor concentration is considered in the physiologically-based pharmacokinetic model (Imamura et al., 2011; Kudo et al., 2013) . The static model inevitably tends to overestimate the impact of DDIs. To overcome this, we proposed a new approach to minimize false-negative prediction of transportermediated DDIs using the static model (Yoshida et al., 2012) . Obviously, IC 50 (or K i ) is a key parameter in both models. Thus, accurate estimation of IC 50 (or K i ) for the target transporter is a crucial step to achieve the quantitative DDI prediction.
Organic anion transporting polypeptide (OATP) 1B1 (SLCO1B1) is specifically expressed in the sinusoidal membrane of hepatocytes and mediates the hepatic uptake of a wide range of drugs, including 3-hydroxymethylglutaryl-CoA reductase inhibitors (statins), angiotensin II receptor blockers, and endothelin receptor antagonists (Abe et al., 1999; Hsiang et al., 1999; Katz et al., 2006; Yamashiro et al., 2006; van Giersbergen et al., 2007; Yamada et al., 2007; Sharma et al., 2012) . It has been reported that genetic polymorphisms of OATP1B1 are associated with interindividual variation in plasma concentration of various statins Niemi et al., 2011) and adverse event rates of statin therapy (Link et al., 2008) . Moreover, clinically relevant DDIs of OATP1B1 substrate drugs (e.g., statins) with cyclosporin A, a single dose of rifampin, and other OATP inhibitors are thought to be attributable to OATP1B1 inhibition (Shitara et al., 2003; Maeda et al., 2011; Niemi et al., 2011) . These cumulative data suggest the clinical importance of OATP1B1 in the drug disposition, and consequently OATP1B1 has been recognized as an important transporter in the International Transporter Consortium white paper and regulatory DDI guidance and guidelines (Giacomini et al., 2010; Center for Drug Evaluation and Research, 2012; Committee for Human Medicinal Products, 2012) .
When evaluating inhibitory potency of compounds of interest on OATP1B1, in vitro assay with OATP1B1-transfected cells using an appropriate probe substrate has been widely conducted. Meanwhile, Noé et al. (2007) reported that inhibitory potency of gemfibrozil on OATP1B1 depends on the substrates employed in their in vitro studies. This suggests that inhibition of OATP1B1 can be over-or underestimated depending on the substrates selected, potentially resulting in false-negative prediction of OATP1B1-mediated DDIs in the worst-case scenario. Thus, we should pay much attention to the OATP1B1 probe substrate for in vitro inhibition assays, as in the case of CYP3A4 (Kenworthy et al., 1999; Obach et al., 2006) , OATP2B1 (Shirasaka et al., 2012) , and OCT2 (Zolk et al., 2009 ). However, limited information is available on the substrate-dependent inhibition of OATP1B1.
Therefore, this study compared the inhibition profiles of 14 compounds for OATP1B1 using prototypical OATP1B1 probe substrates: estradiol-17b-glucuronide (E 2 G), estrone-3-sulfate (E 1 S), and sulfobromophthalein (BSP) that have been widely used for in vitro studies. Furthermore, to provide insight into the binding sites of the three substrates on OATP1B1, mutual inhibition studies were performed. Our results suggested the usefulness of E 2 G as a most likely sensitive in vitro OATP1B1 probe substrate. (Braunschweig, Germany) . Unlabeled E 2 G, E 1 S, BSP, rifampin, taurocholate (TCA), ketoconazole, gemfibrozil, verapamil, and probenecid were purchased from Sigma-Aldrich (St. Louis, MO). Cyclosporin A (CsA), erythromycin, and cimetidine were from Wako Pure Chemical Industries, Ltd., (Osaka, Japan). Tacrolimus was purchased from LKT Laboratories, Inc., (St. Paul, MN), and ritonavir was obtained from Abbott Laboratories (Abbott Park, IL) and used with purification. All other chemicals were of analytical grade and commercially available.
Materials and Methods

Materials
Uptake and Inhibition Studies Using Transfected Cells
The OATP1B1 (SLCO1B1) open reading frame was cloned into the KpnI/ XhoI sites of expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA), and the inserted sequence was confirmed by DNA sequencing. The expression vector with or without OATP1B1 cDNA was transfected into human embryonic kidney 293 cells using lipofectamin 2000 (Invitrogen) according to the manufacturer's protocol. The stably OATP1B1-transfected cells and their control cells were established and maintained in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% (v/v) of fetal bovine serum, penicillin (final concentration 100 units/ml), streptomycin (100 mg/ml), and hygromycin B (80 mg/ml) in a humidified incubator containing 5% CO 2 gas. The cells were trypsinized and uniformly suspended in the desired volume of the culture medium to provide 4 Â 10 5 cells/ml. One ml of the cell suspension was added to each well of a poly-Dlysine-coated 24-well plate (BD Biosciences, San Jose, CA), and the cells were further cultured in the incubator for 48 hours.
The transport study was carried out as described previously (Hirano et al., 2004) . Cell culture medium was replaced with prewarmed Krebs Henseleit (KH) buffer (118 mM NaCl, 23.1 mM NaHCO 3 , 4.83 mM KCl, 0.96 mM KH 2 PO 4 , 1.20 mM MgSO 4 , 12.5 mM HEPES, 5.0 mM glucose, and 1.53 mM CaCl 2 , pH 7.4), and the cells were preincubated for 5 minutes at 37°C. The preincubation buffer was aspirated, and the uptake reaction was initiated by addition of 250 ml of a prewarmed KH buffer containing a radiolabeled substrate with or without a test compound. For inhibition studies with CsA, BSP, ritonavir, rifampin, tacrolimus, E 2 G, and gemfibrozil, each of the dimethylsufoxide (DMSO) original solutions was prepared, serially diluted with DMSO, and 1,000-fold diluted with KH buffer containing a radiolabeled substrate (final DMSO concentration 0.1%). KH buffer containing a radiolabeled substrate and 0.1% DMSO without any inhibitors was used as the solvent control. For E 1 S, erythromycin, TCA, probenecid, and cimetidine, each of the compounds was directly dissolved in KH buffer containing a radiolabeled substrate and serially diluted with KH buffer containing the radiolabeled substrate. For ketoconazole and verapamil, each of the compounds was completely dissolved in KH buffer containing a radiolabeled substrate at acidic pH to prepare the original solution, which was serially diluted with KH buffer containing the radiolabeled substrate to prepare the working solutions. The pH of the working solutions was adjusted at 7.4 before the inhibition assays. KH buffer containing a radiolabeled substrate without any inhibitors was used as the control for inhibition studies with E 1 S, erythromycin, TCA, ketoconazole, verapamil, probenecid, and cimetidine. The uptake was terminated at a designated time point by adding ice-cold KH buffer immediately after removal of the incubation buffer. The cells were washed twice with 1 ml of ice-cold KH buffer and lysed with 0.5 ml of 0.1 N NaOH overnight at room temperature.
The resulting cell lysate was neutralized with 50 ml of 1N HCl. A 400-ml sample of the aliquot was mixed with 4 ml of scintillation fluid (Hionic-Fluor; PerkinElmer Life Sciences), and the radioactivities associated with the cells and incubation buffer were measured with a liquid scintillation counter (Tri-Carb 3100TR; PerkinElmer Life Sciences). Remaining neutralized cell lysate samples were used to quantify protein concentrations (BCA Protein Assay Kit; Thermo Fisher Scientific, Waltham, MA).
Determination of Kinetic Parameters
Uptake of a radiolabeled substrate was expressed as the uptake volume (ml/mg protein), which was given as the radioactivity associated with the cells (dpm/well) divided by the concentration in the incubation buffer (dpm/ml) and the protein amount (mg protein/well). OATP1B1-mediated uptake was obtained by subtracting the uptake into control cells from the uptake into OATP1B1-transfected cells.
Half maximal inhibitory concentration (IC 50 ) of an inhibitor was estimated by examining the inhibitory effect on the uptake of a radiolabeled substrate (% of control) using the following equation:
where CL and CL i represent the uptake clearance in the absence and presence of an inhibitor, respectively, and I (mM) is the concentration of the inhibitor. P was set as a free parameter to achieve the best fit in the nonlinear iterative least squares regression analysis. To the inhibitor which showed biphasic inhibition for OATP1B1, the following equation was applied:
where IC 50,1 and IC 50,2 represent IC 50 values for high-and low-affinity components, respectively. P 1 and P 2 are parameters for high-and low-affinity components, and P 1 / (P 1 + P 2 ) and P 2 / (P 1 + P 2 ) represent the contribution of high-and low-affinity components, respectively. Substrate concentrations employed in this study were sufficiently lower than their K m values, where IC 50 theoretically approximates the K i regardless of inhibition mechanisms, except in the case of uncompetitive inhibition (Ito et al., 1998) . However, as some tested compounds showed not only inhibition, but also stimulation of a substrate uptake, the term IC 50 was used throughout this study. The parameters were estimated by a nonlinear least-squares regression method using the MULTI program (Yamaoka et al., 1981) and expressed as the mean 6 computer-calculated S.D.
Concentration dependence of the uptake of a substrate mediated by OATP1B1 was analyzed using the following Michaelis-Menten equation:
where v, S, K m , and V max represent uptake velocity of the substrate (pmol/ min/mg protein), the substrate concentration in the incubation buffer (mM), Michaelis constant (mM), and the maximum uptake rate (pmol/min/mg protein), respectively. When nonsaturable component was observed, the following equation was used for the analysis:
where P dif represents nonsaturable uptake clearance (ml/min/mg protein).
Fitting was performed by a nonlinear least-squares regression method using the MULTI program.
Statistical Analysis
The data are presented as mean 6 S.D. One-way analysis of variance followed by Dunnett's post hoc test was used to identify significant differences between groups where appropriate. P , 0.05 was considered significant. Fig. 3 . As shown in Fig. 3, A 
Results
Uptake of Prototypical OATP1B1 Substrates by OATP1B1-Transfected Cells
Discussion
It has been demonstrated that membrane transporters play significant roles in drug disposition, therapeutic efficacy, and adverse events, and clinical evidence showing the importance of transportermediated DDIs is increasingly accumulating (Giacomini et al., 2010; Yoshida et al., 2013) . OATP1B1 is one of the major human hepatic uptake transporters, and clinically observed DDIs involving OATP1B1 have been reported (Shitara et al., 2003; Maeda et al., 2011; Niemi et al., 2011; Shitara et al., 2013) . Regulatory agencies also consider OATP1B1 as one of the important transporters (Committee for Human Medicinal Products, 2012; Center for Drug Evaluation and Research, 2012). Selection of the OATP1B1 probe substrate for in vitro study is important for predicting the DDI risk.
E 2 G and E 1 S are prototypical OATP1B1 probe substrates and are widely used in cellular uptake studies with OATP1B1-transfected cells and human hepatocytes (Hirano et al., 2004; Sharma et al., 2010) . OATP1B1-transfected cells used in this study also showed significantly Table 1 , and each point represents the mean 6 S.D. The solid line and the dashed lines represent the line of unity and the lines of 1:10 and 10:1 correlations, respectively. 1, E 1 S; 2, CsA; 3, BSP; 4, ritonavir; 5, rifampin; 6, tacrolimus; 7, erythromycin; 8, E 2 G; 9, ketoconazole; 10, TCA; 11, verapamil; 12, gemfibrozil; and 13, probenecid. IC 50 H]E 1 S was used as a substrate, respectively, and a similar trend was also reported previously (Noé et al., 2007; Soars et al., 2012) . Also, to a lesser extent, CsA produced a 6-fold greater IC 50 H]E 2 G uptake, but the difference was within 3-fold. These substrate-dependent differences in IC 50 , particularly for rifampin and CsA, which are used clinically as OATP inhibitors, should be taken into account in accurately estimating the impact of OATP1B1-mediated DDIs.
BSP is also a typical OATP1B1 substrate (Cui et al., 2001; Kindla et al., 2011) and showed significantly higher uptake in OATP1B1-transfected cells compared with the control cells (Fig. 1) (Fig. 3B) 3 H]E 2 G. These results clearly indicate substrate-dependent interaction with OATP1B1, and some inhibitors (ritonavir, gemfibrozil, erythromycin, and rifampin) caused more than 10-fold differences in the IC 50 values. This means OATP1B1-mediated DDI risk can be more than 10-fold underestimated if the substrate is not appropriately selected, which could result in false-negative DDI prediction and potentially serious clinical safety issues. Thus, careful attention will be needed when selecting an OATP1B1 probe substrate for in vitro inhibition assay, as in the case of CYP3A4 (Kenworthy et al., 1999; Obach et al., 2006) , OATP2B1 (Shirasaka et al., 2012) , and OCT2 (Zolk et al., 2009) . Although it would be ideal to evaluate DDI potentials for all OATP1B1 substrate-inhibitor combinations anticipated in clinical settings, this H]BSP uptake increased by 17-and 5-fold, respectively. These results suggest more than one binding site on OATP1B1, which might be an underlying mechanism of substrate-dependent inhibition of OATP1B1. Further kinetic analysis with molecular biology techniques as reported previously (Miyagawa et al., 2009) will be needed to identify each binding site of E 2 G, E 1 S, and BSP, and clarify the complex mutual interactions among them on OATP1B1.
In the inhibition studies, some compounds, such as E 1 S, ritonavir, and E 2 G, caused not only inhibition at higher concentrations, but also statistically significant stimulation of the substrate uptake at lower concentrations (Supplemental Tables 1, 2 , and 3), and this behavior was more evident in [ 3 H]BSP uptake (Fig. 2) . Cimetidine was also found to significantly stimulate [ 3 H]BSP uptake, but the stimulatory effect was sustained over the concentration range from 3 mM to 1,000 mM (Supplemental Table 3 ). Although the underlying mechanism of the observed stimulation remains to be clarified, the inhibitors at lower concentrations might have dominantly interacted with the allosteric site, resulting in stimulation of [ 3 H]BSP uptake, while the inhibitors at higher concentrations, except cimetidine, might have not only interacted with the allosteric site, but also inhibited the BSP binding site, resulting in net inhibition of [ 3 H]BSP uptake. Sustained stimulation of OATP1B1-mediated [ 3 H]BSP uptake by cimetidine over the concentration range from 3-1,000 mM might be explainable in terms of the preferential affinity of cimetidine for an allosteric site relative to BSP binding site. Although further studies will be needed to draw more definite conclusions, the significant stimulatory effect observed in this study and another study (Kindla et al., 2011) suggests the presence of multiple binding sites on OATP1B1.
In conclusion, inhibition potentials of 14 compounds on OATP1B1 were comparatively analyzed using the prototypical OATP1B1 probe substrates E 2 G, E 1 S, and BSP, and OATP1B1 showed substratedependent inhibition. Some inhibitors showed more than 10-fold differences in the IC 50 values depending on the substrate used in the in vitro inhibition studies. Among the three substrates tested, E 2 G was the OATP1B1 probe substrate that could most sensitively detect inhibitory potential on OATP1B1. E 2 G could be used as a sensitive probe substrate when evaluating OATP1B1 inhibition, which will help mitigate the risk of false-negative DDI prediction.
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Inhibitor concentrations, at which OATP1B1-mediated uptake of [ 3 H]E1S (0.01 μM) was significantly stimulated in inhibition studies (Fig. 2) , are highlighted in bold. *P < 0.05, **P < 0.01, ***P < 0. 
